Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Niraparib, an orally-administered PARP inhibitor, is currently being investigated for the treatment of patients with metastatic castration-resistant prostate cancer and BRCA1/2 DNA repair gene defects
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Pharmaceuticals | Prostate Cancer